1.
Bhadhuri A, Insinga R, Guggisberg P, Panje C, Schwenkglenks M. Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland. Swiss Med Wkly [Internet]. 2019 Dec. 27 [cited 2024 May 21];149(5152):w20170. Available from: https://smw.ch/index.php/smw/article/view/2711